Fumarate treatment in progressive forms of multiple sclerosis: First results of a single-center observational study

Therapeutic Advances in Neurological Disorders

Volumn 7, Issue 5, 2014, Pages 232-238

  Strassburger Krogias, Katrin ^a   Ellrichmann, Gisa ^a   Krogias, Christos ^a   Altmeyer, Peter ^a   Chan, Andrew ^a   Gold, Ralf ^a  

^a ST JOSEF HOSPITAL   (Germany)

Author keywords

antioxidative; cytoprotective; fumarate; neurodegeneration; progressive multiple sclerosis

Indexed keywords

FUMADERM; FUMARIC ACID DIMETHYL ESTER;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; GENERAL CONDITION DETERIORATION; HOT FLUSH; HUMAN; KIDNEY FUNCTION; LEUKOPENIA; LIVER FAILURE; LIVER FUNCTION; LYMPHOCYTOPENIA; MALE; MEDICATION COMPLIANCE; MULTIPLE SCLEROSIS; NAUSEA AND VOMITING; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PILOT STUDY; PROSPECTIVE STUDY; PROTEINURIA; PRURITUS; RHINORRHEA; TIME TO TREATMENT; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; VOMITING;

EID: 84910027119     PISSN: 17562856     EISSN: 17562864     Source Type: Journal    
DOI: 10.1177/1756285614544466     Document Type: Article

References (20)

1. Andersen O. Elovaara I. Färkkilä M. et al. (2004) Multicentre, randomized, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 75: 706–710.
2. Comi G. (2013) Disease-modifying treatments for progressive multiple sclerosis. Multiple Sclerosis J 19:1428–1436.
3. Ellrichmann G. Petrasch-Parwez E. Lee D. Reick C. Arning L. Saft C. et al. (2011) Efficacy of fumaric acid esters in the R6/2 and YAC 128 models of Huntington's disease. PloS ONE 6: e16172.
4. Fox R.M. Miller D.H. Phillips J. Hutchinson M. Havrdova E. Kita M. et al. (2012) Placebo-controlled phase 3 study of oral BG-12 or Glatiramer in Multiple Sclerosis. N Engl J Med 367: 1087–1097.
5. Gilgun-Sherki Y. Melamed E. Offen D. et al (2004) The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J Neurol 251: 261–268.
6. Gold R. Kappos L. Arnold D. et al. (2012) Placebo controlled phase 3 study of oral BG 12 for relapsing multiple sclerosis. N Engl J Med 367: 1098–1107.
7. Hartung H. Gonsette R. König N. et al. (2002) Mitoxantrone in Multiple Sclerosis Study Group (MIMS). Mitoxantrone in progressive multiple sclerosis: a placebo- controlled, double-blind randomized multicentre trial. Lancet 360: 2018–2025.
8. Hawker K. O'Connor P. Freedman M. et al. (2009) Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 66: 460–471.
9. Johnson D. Amirahmadi S. Ward C. (2010) The absence of the pro-antioxidant transcription factor Nrf 2 exacerbated experimental autoimmune encephalomyelitis. Toxicol Sci 114: 237–246.
10. Koch-Henriksen N. Sørensen P. (2010) The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 9: 520–532.
11. Krutzke J. (1983) Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 33: 1444–1452.
12. La Mantia L. Vacchi L. Di Pietrantonj C. et al (2012) Interferon beta for secondary progressive multiple sclerosis. Cochrane Database Syst Rev (1): CD005181.
13. Lassmann H. (2013) Multiple sclerosis: lessons from molecular neuropathology. Exp Neurol 14 December (epub ahead of print).
14. Linker R. Lee D. Ryan S. et al. (2011) Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf antioxidant pathway. Brain 134: 678–692.
15. Lublin F. Reingold S. (1996) Defining the clinical course of multiple sclerosis: results of an international Survey. Neurology 46: 907–911.
16. Montalban X. Sastre-Garriga J. Tintore M. Brieva L. Aymerich F.X. Río J. et al. (2009) A single- center randomized, double- blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. Mult Scler 15: 1195–1205.
17. Polman C. Reingold S. Edan G. et al. (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the ‘McDonald Criteria’. Ann Neurol 58: 840–846.
18. Scannevin T. Brennan M. Matos M. et al. (2014) Dimethyl fumarate and monoethyl fumarate exhibit differential effects on glutathione, Keap 1 and Nrf 2 activation in vitro. Neurology 82: P1.204
19. Schimrigk S. Brune N. Hellwig K. et al. (2006) Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur J Neurol 13: 604–610.
20. Thompson A. Toosy A. Ciccarelli O. (2010) Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions. Lancet Neurol 9: 1182–1199.